Carregant...
Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
Immune checkpoint inhibitors (ICIs) belong to a new group of anticancer drugs targeting T-cell proteins involved in the activation of immune response toward malignancies. Their introduction into clinical practice was a milestone in modern cancer treatment. However, the significant advantage of ICIs...
Guardat en:
Autors principals: | , |
---|---|
Format: | Artigo |
Idioma: | Inglês |
Publicat: |
Bioscientifica
2020-10-01
|
Col·lecció: | Endocrine Connections |
Matèries: | |
Accés en línia: | https://ec.bioscientifica.com/view/journals/ec/9/10/EC-20-0342.xml |
Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|